Neuphoria Therapeutics (NEUP) vs Tvardi Therapeutics (TVRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neuphoria Therapeutics (NEUP) has outperformed Tvardi Therapeutics (TVRD) over the past year, losing 47.3% versus a loss of 74.8%. Tvardi Therapeutics is the larger company by market cap ($13.2 million vs $12.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NEUP | TVRD |
|---|---|---|
| Share price | $2.35 | $0.9893 |
| Market cap | $12.72M | $13.22M |
| 1-day change | +1.29% | +4.57% |
| YTD return | -39.43% | -76.99% |
| 1-year return | -47.31% | -74.76% |
| 5-year return | — | -99.79% |
| EPS (TTM) | $-2.07 | $-2.69 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.17M | — |
| Revenue growth (YoY) | -92.50% | — |
| Net income (latest FY) | $-13.45M | $-18.21M |
| Operating margin | -1401.09% | — |
| Net margin | -1145.66% | — |
| 52-week high | $5.53 | $5.69 |
| 52-week low | $2.26 | $0.773 |
| Distance from 52-week high | -57.50% | -82.61% |
| Analyst consensus | none | buy |
| Avg. price target upside | — | +835.00% |
| Average volume | 26.53K | 235.95K |
| Shares outstanding | 5.41M | 13.36M |
| Employees | 1 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEUP has outperformed TVRD by 27.5 percentage points over the past year.
About Neuphoria Therapeutics
NEUP stock →Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
About Tvardi Therapeutics
TVRD stock →Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
NEUP vs TVRD FAQ
Which is bigger, Neuphoria Therapeutics or Tvardi Therapeutics?
Tvardi Therapeutics (TVRD) is larger, with a market capitalization of $13.22M compared with $12.72M for Neuphoria Therapeutics (NEUP).
Which stock has performed better over the past year, NEUP or TVRD?
NEUP returned -47.31% over the past 12 months, compared with -74.76% for TVRD (price return, excluding dividends). Past performance does not predict future results.
Are Neuphoria Therapeutics and Tvardi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.